Special Issue "Antimicrobial Peptides: Therapeutic Potentials"

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 15 December 2019

Special Issue Editor

Guest Editor
Dr. Kai Hilpert

Institute of Infection and Immunity, St George's University of London, London, UK
Website | E-Mail
Interests: antimicrobial peptides; anti-fungal peptides; anticancer peptides; MDR Pseudomonas aeruginosa; MRSA; MDR E. coli; VRE; peptide libraries; SPOT synthesis

Special Issue Information

Dear Colleagues,

The WHO has classified antimicrobial resistance as one of the biggest threats to global health, food security, and development today (http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/). Currently, about 700,000 to 1,000,000 people die worldwide each year because of resistant infections. In the O’Neil Report it is estimated that by 2050 these numbers will increase to 10,000,000, more people than currently killed by cancer. It is estimated that the additional health care cost for this impact will reach US$100 trillion. The situation might even intensify since the number of newly-developed antibiotics is steadily declining. FDA approval of new antimicrobials dropped to three new molecular entities (NME) in this decade. One reason for this is that most major pharmaceutical companies have stalled their research efforts for new antimicrobial compounds. In 1985 more than 30 companies undertook active anti-bacterial programs, whereas in 2013 it was less than 10.

Antimicrobial peptides (AMPs) have been recognised for their ability to kill multidrug resistant bacteria and do not easily induce resistance, two features that makes them very attractive as drug candidates. In addition, the overall peptide drug market is steadily growing, from US$18.9 billion in 2013 to US$23.7 billion in 2020. This has led to improved scale up technologies and new large-scale GMP facilities and innovative drug administration regimes. Supported by the price increase for novel antimicrobials and the “ready to use” technology, antimicrobial peptides can become a viable option for urgently needed new antimicrobial drugs. In the last two decades of AMP research, it became clear that these molecules have multiple biological activities, like antimicrobial, antiparasitic, anticancer and immunomodulatory. In the same time period, multiple targets of AMPs for their antibacterial activities were discovered.

In this Special Issue of Microorganisms, we invite you to send contributions concerning any biological activities related to the therapeutic potential of antimicrobial peptides, including direct (e.g. killing of pathogens/parasites/cancer cells) and indirect (e.g. immunomodulatory effects) modes of action.

Dr. Kai Hilpert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antimicrobial peptides
  • Host defence peptides
  • Multi-drug resistant bacteria
  • Novel antimicrobials
  • Immunomodulation
  • Immunotherapy
  • Anticancer peptides
  • Antiparasitic peptides
  • Antifungal peptides
  • Wound healing peptides

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Methods and Challenges of Using the Greater Wax Moth (Galleria mellonella) as a Model Organism in Antimicrobial Compound Discovery
Microorganisms 2019, 7(3), 85; https://doi.org/10.3390/microorganisms7030085
Received: 22 February 2019 / Revised: 8 March 2019 / Accepted: 14 March 2019 / Published: 19 March 2019
PDF Full-text (3250 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Among non-mammalian infection model organisms, the larvae of the greater wax moth Galleria mellonella have seen increasing popularity in recent years. Unlike other invertebrate models, these larvae can be incubated at 37 °C and can be dosed relatively precisely. Despite the increasing number [...] Read more.
Among non-mammalian infection model organisms, the larvae of the greater wax moth Galleria mellonella have seen increasing popularity in recent years. Unlike other invertebrate models, these larvae can be incubated at 37 °C and can be dosed relatively precisely. Despite the increasing number of publications describing the use of this model organism, there is a high variability with regard to how the model is produced in different laboratories, with respect to larva size, age, origin, storage, and rest periods, as well as dosing for infection and treatment. Here, we provide suggestions regarding how some of these factors can be approached, to facilitate the comparability of studies between different laboratories. We introduce a linear regression curve correlating the total larva weight to the liquid volume in order to estimate the in vivo concentration of pathogens and the administered drug concentration. Finally, we discuss several other aspects, including in vivo antibiotic stability in larvae, the infection doses for different pathogens and suggest guidelines for larvae selection. Full article
(This article belongs to the Special Issue Antimicrobial Peptides: Therapeutic Potentials)
Figures

Figure 1

Microorganisms EISSN 2076-2607 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top